AB
AARD

Amalgamated Bank’s Aardvark Therapeutics AARD Stock Holding History

Amalgamated Bank’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$5K – 2921
2025
Q4 		$5K Buy
400
+207
+107% +$2.58K ﹤0.01% 2750
2025
Q3 		$3K Hold
193
– – ﹤0.01% 2915
2025
Q2 		$3K Buy
+193
New +$1.99K ﹤0.01% 2944

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Amalgamated Bank's AARD Position: Q1 2026 in Review

Amalgamated Bank sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 400 shares — an estimated $5K sold.

Amalgamated Bank first reported a position in AARD in Q2 2025 and held it in 3 quarters. The position peaked at $5K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Amalgamated Bank reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 400 Aardvark Therapeutics shares in Q1 2026, an estimated $5K.
  • Amalgamated Bank first reported a position in Aardvark Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Aardvark Therapeutics position peaked at $5K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.